Download This PaperThe Impact of Pharmaceutical Innovation on Longevity and Medical Expenditure in Sweden, 1997-2010: Evidence from Longitudinal, Disease-Level Data
43 Pages Posted: 22 Aug 2012
Date Written: July 31, 2012
Abstract
We use longitudinal, disease-level data to analyze the impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, where mean age at death increased by 1.88 years during the period 1997-2010. Pharmaceutical innovation is estimated to have increased mean age at death by 0.60 years during the period. The estimates indicate that longevity depends on the number of drugs to treat a disease, not the number of drug classes. Pharmaceutical innovation also reduced hospital utilization in Sweden, so the cost per life-year gained from the introduction of new drugs was quite low.
Keywords: longevity, pharmaceutical, innovation, drugs, Sweden
JEL Classification: I120, J110, L650, O330
Suggested Citation: Suggested Citation
Frank R. Lichtenberg (Contact Author)
Columbia University - Columbia Business School, Finance ( email )
3022 Broadway
504 Uris Hall, Dept. of Finance & Economics
New York, NY 10027
United States
212-854-4408 (Phone)
212-316-9219 (Fax)
HOME PAGE: http://https://www8.gsb.columbia.edu/cbs-directory/detail/frl1
CESifo (Center for Economic Studies and Ifo Institute for Economic Research)
Poschinger Str. 5
Munich, DE-81679
Germany